Inoda, Satoru
Takahashi, Hidenori http://orcid.org/0000-0001-5331-4730
Inoue, Yuji
Tan, Xue
Tampo, Hironobu
Arai, Yusuke
Yanagi, Yasuo
Kawashima, Hidetoshi
Article History
Received: 3 July 2021
Revised: 28 September 2021
Accepted: 4 October 2021
First Online: 29 October 2021
Declarations
:
: All procedures performed in studies involving human participants were in accordance with ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The study was approved by the institutional review boards of the Japan Community Healthcare Organization Tokyo Shinjuku Medical Center and Jichi Medical University (CU20-R007, H22-3)
: Informed consent was obtained from all individual participants included in this study.
: The authors affirm that human research participants provided informed consent for publication of the images in Figures InternalRef removed, InternalRef removed, and InternalRef removed.
: SI, XT, HT, and YA have no relevant financial or non-financial interests to disclose.HT is a consultant to Kowa Pharmaceutical, Novartis Pharmaceutical, Bayer Pharmaceutical, Senju Pharmaceutical, Pfizer Pharmaceutica, and Santen Pharmaceutical, and a founder of DeepEyeVision Inc.YI is a consultant to Novartis Pharmaceuticals, Mitsubishi-Tanabe Pharmaceutical, and the Tochigi Prefectural Ophthalmologists Association.YY is a consultant to Novartis Pharmaceuticals, Bayer Yakuhin, Santen Pharmaceuticals, and Senju Pharmaceutical.HK is a consultant to Kowa Pharmaceutical, Novartis Pharmaceuticals, Santen Pharmaceutical, Mitsubishi-Tanabe Pharmaceutical, Senju Pharmaceutical, and the Tochigi Prefectural Ophthalmologists Association.